The MaxCyte® STX™ Scalable Transfection System allows users to transfect up to 1×1010 cells with single or multiple plasmids encoding GPCRs, ion channels and other targets. The technology overcomes the time and cost constraints of assay development with stable cells. It also allows expression of toxic proteins and enables assay development with physiologically relevant cell types, including primary cells, stem cells and cells of hematopoietic origin. Below, we discuss some of the factors that are important for developing a successful cell-based assay using the MaxCyte STX.
Learn about cutting-edge applications, new resources, and upcoming events.
Subscribe to our e-Newsletter